PG
VRTX icon

PEAK6 Group’s Vertex Pharmaceuticals VRTX Stock Holding History

PEAK6 Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$3.54M Sell
20,800
-5,900
-22% -$915K 0.02% 975
2018
Q1 		$4.35M Sell
26,700
-29,700
-53% -$4.85M 0.02% 881
2017
Q4 		$8.45M Buy
56,400
+10,000
+22% +$1.48M 0.04% 551
2017
Q3 		$7.05M Sell
46,400
-29,600
-39% -$4.46M 0.04% 569
2017
Q2 		$9.79M Buy
76,000
+39,400
+108% +$4.74M 0.06% 391
2017
Q1 		$4M Sell
36,600
-47,600
-57% -$4.19M 0.03% 686
2016
Q4 		$6.2M Buy
84,200
+27,000
+47% +$2.2M 0.04% 586
2016
Q3 		$4.99M Buy
57,200
+4,100
+8% +$387K 0.04% 692
2016
Q2 		$4.57M Buy
53,100
+16,300
+44% +$1.41M 0.04% 723
2016
Q1 		$2.92M Sell
36,800
-42,500
-54% -$3.84M 0.02% 924
2015
Q4 		$9.98M Sell
79,300
-22,100
-22% -$2.67M 0.07% 365
2015
Q3 		$10.6M Buy
101,400
+27,900
+38% +$3.58M 0.06% 445
2015
Q2 		$9.08M Sell
73,500
-3,800
-5% -$479K 0.05% 490
2015
Q1 		$9.12M Sell
77,300
-80,900
-51% -$9.69M 0.07% 366
2014
Q4 		$18.8M Sell
158,200
-9,800
-6% -$1.1M 0.14% 143
2014
Q3 		$18.9M Buy
168,000
+85,400
+103% +$8.13M 0.15% 136
2014
Q2 		$7.82M Sell
82,600
-16,500
-17% -$1.16M 0.07% 332
2014
Q1 		$7.01M Sell
99,100
-27,800
-22% -$2.2M 0.06% 429
2013
Q4 		$9.43M Buy
126,900
+23,100
+22% +$1.61M 0.07% 350
2013
Q3 		$3.94M Buy
103,800
+76,300
+277% +$6.07M 0.03% 964
2013
Q2 		$2.2K Buy
+27,500
New +$2.03M 0.01% 1440

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Group's VRTX Position: Q1 2018 in Review

PEAK6 Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 15,094 shares — an estimated $2.47M sold.

PEAK6 Group first reported a position in VRTX in Q2 2013 and held it in 12 quarters. The position peaked at $3.47M in Q1 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • PEAK6 Group reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • PEAK6 Group sold 15,094 Vertex Pharmaceuticals shares in Q1 2018, an estimated $2.47M.
  • PEAK6 Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • PEAK6 Group's Vertex Pharmaceuticals position peaked at $3.47M in Q1 2017.
  • 680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.